GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Asset Turnover

Protalix BioTherapeutics (Protalix BioTherapeutics) Asset Turnover : 0.12 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Protalix BioTherapeutics's Revenue for the three months ended in Dec. 2023 was $10.49 Mil. Protalix BioTherapeutics's Total Assets for the quarter that ended in Dec. 2023 was $86.00 Mil. Therefore, Protalix BioTherapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.12.

Asset Turnover is linked to ROE % through Du Pont Formula. Protalix BioTherapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -67.33%. It is also linked to ROA % through Du Pont Formula. Protalix BioTherapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -28.11%.


Protalix BioTherapeutics Asset Turnover Historical Data

The historical data trend for Protalix BioTherapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Asset Turnover Chart

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 1.11 0.54 0.74 0.93

Protalix BioTherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.16 0.45 0.12 0.12

Competitive Comparison of Protalix BioTherapeutics's Asset Turnover

For the Biotechnology subindustry, Protalix BioTherapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Asset Turnover falls into.



Protalix BioTherapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Protalix BioTherapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=65.494/( (55.787+84.434)/ 2 )
=65.494/70.1105
=0.93

Protalix BioTherapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=10.486/( (87.569+84.434)/ 2 )
=10.486/86.0015
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Protalix BioTherapeutics  (AMEX:PLX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Protalix BioTherapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-24.176/35.908
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-24.176 / 41.944)*(41.944 / 86.0015)*(86.0015/ 35.908)
=Net Margin %*Asset Turnover*Equity Multiplier
=-57.64 %*0.4877*2.3951
=ROA %*Equity Multiplier
=-28.11 %*2.3951
=-67.33 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Protalix BioTherapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-24.176/86.0015
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-24.176 / 41.944)*(41.944 / 86.0015)
=Net Margin %*Asset Turnover
=-57.64 %*0.4877
=-28.11 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Protalix BioTherapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Executives
Dror Bashan director, officer: President and CEO 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben director 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin officer: Sr. VP and CFO C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos officer: Sr. VP, Operations 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon officer: Vice President, R&D 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld director 6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot director 6225 NEIL ROAD, RENO NV 89511
Pol F Boudes director C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor officer: President & CEO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100